SCHEMBL13748880

SCHEMBL13748880

CCC(O)C(C)C1OC1CC(C)/C=C/C=C(\C)C1OC(=O)CC(O)CCC(C)(C)C(OC(C)=O)/C=C/C1C

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SF3B3 Q15393 10/20 0.71
HMGCR P04035 2/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
TSHR P16473 2/20 0.31
ABCB11 O95342 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPK1 P28482 1/20 0.31
MTOR P42345 1/20 0.31
HTT P42858 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
GMNN O75496 1/20 0.31
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
NFKB1 P19838 1/20 0.31
BLM P54132 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12877318 0.94 SF3B3 (0.76) SF3B3HMGCRMEN1KMT2ASMN1; SMN2
SCHEMBL14539614 0.94 SF3B3 (0.76) SF3B3HMGCRMEN1KMT2ASMN1; SMN2
SCHEMBL30311586 0.94 SF3B3 (0.76) SF3B3HMGCRMEN1KMT2ASMN1; SMN2
SCHEMBL905749 0.94 SF3B3 (0.76) SF3B3HMGCRMEN1KMT2ASMN1; SMN2
SCHEMBL12877481 0.94 SF3B3 (0.76) SF3B3HMGCRMEN1KMT2ASMN1; SMN2
SCHEMBL13503211 0.94 SF3B3 (0.62) SF3B3HMGCR
SCHEMBL12833633 0.93 SF3B3 (0.69) SF3B3HMGCRMEN1KMT2ASMN1; SMN2
SCHEMBL1505041 0.93 SF3B3 (0.69) SF3B3HMGCRMEN1KMT2ASMN1; SMN2
SCHEMBL3626331 0.93 SF3B3 (0.68) SF3B3HMGCR
SCHEMBL3617692 0.93 SF3B3 (0.68) SF3B3HMGCRMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215134-A1 Genetically modified microorganism and process for production of macrolide compound using the microorganism EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-08-27 US disclosed
US-20090215134-A1 Genetically modified microorganism and process for production of macrolide compound using the microorganism EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215134-A1 Genetically modified microorganism and process for production of macrolide compound using the microorganism CYP4A22, CYP46A1, CYP51A1 SF3B3 2769/4885HMGCR 104/4885MEN1 1284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.